$10.92−0.45 (−3.96%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Janux Therapeutics (JANX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 5.6% in FY25, net margin −1136.2%. Worth your attention in FY25: Share count (+163.4%) and Capex step-up ($1.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼5.6%
10.0
FY21→FY25CAGR +28.8%/yr
Net income ($M)▼64.7%
−113.6
FY21→FY25CAGR —
Free cash flow ($M)▼88.5%
−83.3
capex stepped upCAGR —
Diluted EPS▼43.0%
−1.83
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+163.4%
23.5mn → 62.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$1.0M
▲191% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-1136¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -1136.3% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 23,289.0 | 10,000.0 | 10,588.0 | 8,083.0 | 8,612.0 | 3,637.0 | ▼5.6% | +28.8% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 23,289.0 | 10,000.0 | 10,588.0 | 8,083.0 | 8,612.0 | 3,637.0 | ▼5.6% | +28.8% |
Research & development | 119,920.0 | 125,896.0 | 68,388.0 | 54,922.0 | 53,441.0 | 26,237.0 | ▲84.1% | +48.0% |
Selling, general & admin | 42,931.0 | 41,771.0 | 41,047.0 | 26,140.0 | 22,262.0 | 10,329.0 | ▲1.8% | +41.8% |
Total operating expenses | 162,851.0 | 167,667.0 | 109,435.0 | 81,062.0 | 75,703.0 | 36,566.0 | ▲53.2% | +46.3% |
Operating incomefeeds ROC rank | −139,562.0 | −157,667.0 | −98,847.0 | −72,979.0 | −67,091.0 | −32,929.0 | ▼59.5% | — |
Other income, net | 39,713.0 | 44,042.0 | 29,853.0 | 14,686.0 | 4,032.0 | 257.0 | — | — |
Pretax income | −99,849.0 | −113,625.0 | −68,994.0 | −58,293.0 | −63,059.0 | −32,672.0 | ▼64.7% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −99,849.0 | −113,625.0 | −68,994.0 | −58,293.0 | −63,059.0 | −32,672.0 | ▼64.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.59 | −1.83 | −1.28 | −1.32 | −1.52 | −1.39 | ▼43.0% | — |
Diluted shares (mn) | 63.09 | 61.97 | 53.75 | 44.02 | 41.47 | 23.53 | ▲15.3% | +27.4% |
| Margins | ||||||||
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −599.3% | −1576.7% | −933.6% | −902.9% | −779.0% | −905.4% | ▼643.1pp | −671.3pp |
Net margin5th pct in Healthcare | −428.7% | −1136.3% | −651.6% | −721.2% | −732.2% | −898.3% | ▼484.6pp | −237.9pp |
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Janux Therapeutics' revenue last fiscal year?
Janux Therapeutics reported revenue of $10.0M in fiscal 2025, down 5.6% from fiscal 2024.
What was Janux Therapeutics' net income?
Janux Therapeutics reported net income of −$113.6M in fiscal 2025, a net margin of −1136.3%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

